Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > So.far.only fda
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(45)
•••
Comment by Annayyaon Jun 09, 2021 2:44pm
149 Views
Post# 33356352

RE:RE:RE:RE:RE:So.far.only fda

RE:RE:RE:RE:RE:So.far.only fdaI used to gamble with the buy / sell, increasing and decreasing positions based on news but I think we are at the most important time in this company's history so I am holding everything and increasing my position when I can. This is not the time to play tricks for pennies. Aducanumab being approved removes the biggest risk on this stock, so now it's just a matter of days or few weeks for the big news on the partner or huge funding to start Phase 1 for PMN310.
DavidKingCanada wrote: I'm not too sure if the Elliott or Gene have all the say especially when the Stock has trippled since YTD. At the end of the Day you are dealing with a Penny Stock. If you play your Cards right and cash out at the High and wait 1 Week and Buy for a few Pennies Lower you will Increase your Number of Shares. PMN.to ARFXF are Long Term Holds (3-5 Years). 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities